Central Cancer Registry Reporting Content IG, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-central-cancer-registry-reporting-ig/ and changes regularly. See the Directory of published versions
Narrative
status: completed
category: Outpatient
medication: rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection
subject: Amy Shaw
effective: 2018-04-22
Performer: Joseph Nichols
reasonReference: Condition-primary-cancer-condition-breast
authoredOn: 2018-04-12
note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.
Route: SNOMED 47625008 Intravenous route (qualifier value)
Dose: 105.96 mg